{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:10:39Z","timestamp":1789665039448,"version":"4.0.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune diseases involve disruptions in immune tolerance, persistent systemic inflammation, and progressive multi-organ involvement, with increasing global prevalence. Accurate prediction of disease flares and complications, alongside tools for activity stratification, represents a significant clinical challenge. C-reactive protein (CRP), a canonical pattern recognition molecule of the pentraxin family, is a widely employed inflammatory biomarker; however, its expression patterns, cellular origins, and disease-specific roles across autoimmune conditions have not been comprehensively assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study integrated retrospective clinical cohort analyses from Nanjing Drum Tower Hospital with population-level data from the National Health and Nutrition Examination Survey, proteomic profiling, and single-cell RNA sequencing to examine CRP expression across multiple autoimmune diseases, including systemic lupus erythematosus, Sj\u00f6gren\u2019s disease, autoimmune hepatitis, and various inflammatory arthritides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical data indicate that CRP levels exhibit considerable heterogeneity across these conditions. Proteomic analyses identify CRP as a core inflammatory mediator in conditions such as rheumatoid arthritis, while single-cell RNA sequencing delineates its major cellular sources. Integration of population-level data supports these heterogeneous patterns and demonstrates positive correlations between CRP levels and systemic inflammatory burden, as well as associations with hematologic parameters. Additionally, liver-derived single-cell and spatial transcriptomic data offer insights into the tissue-specific inflammatory landscape in autoimmune hepatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, this study maps the CRP expression landscape across multiple autoimmune diseases and identifies cellular sources in specific disease contexts. These findings indicate that CRP interpretation in autoimmune settings requires consideration of both disease type and clinical context, which may inform more refined strategies for early detection and patient stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1831536","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:53Z","timestamp":1778473433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Expression characteristics of C-reactive protein in autoimmune diseases and their complications"],"prefix":"10.3389","volume":"17","author":[{"given":"Qianyue","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Central Hospital of Shaoyang","place":["Shaoyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuting","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103408","article-title":"Intermittent fasting: a promising dietary intervention for autoimmune diseases","volume":"22","author":"Barati","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.34133\/research.1097","article-title":"The gut microbiota: emerging evidence in autoimmune and inflammatory diseases","volume":"9","author":"Zeng","year":"2026","journal-title":"Res (Wash D C)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.37","article-title":"C-reactive protein in rheumatology: biology and genetics","volume":"7","author":"Rhodes","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13641","article-title":"Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease","volume":"84","author":"Li","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B6","article-title":"Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis","volume":"20","author":"Gabay","year":"1993","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0031-3025(16)32693-9","article-title":"High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus","volume":"65","author":"Mok","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0307-742x(21)00201-0","article-title":"C-reactive protein in SLE","volume":"8","author":"Pepys","year":"1982","journal-title":"Clin Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622326","article-title":"C-reactive protein levels in systemic lupus erythematosus are modulated by the interferon gene signature and CRP gene polymorphism rs1205","volume":"11","author":"Enocsson","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4059-5","article-title":"C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population","volume":"37","author":"Atisha-Fregoso","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.102998","article-title":"Conformational state of C-reactive protein is critical for reducing immune complex-triggered type I interferon response: implications for pathogenic mechanisms in autoimmune diseases imprinted by type I interferon gene dysregulation","volume":"135","author":"Svanberg","year":"2023","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06430-6","article-title":"Association of - 717 A > G (rs2794521) CRP polymorphism with high cardiovascular risk by C-reactive protein in systemic lupus erythematosus patients","volume":"42","author":"Pesqueda-Cendejas","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-022-02831-9","article-title":"Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity","volume":"24","author":"Karlsson","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103073","article-title":"Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP","volume":"139","author":"Karlsson","year":"2023","journal-title":"J Autoimmun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2017.03.010","article-title":"Antibodies against monomeric C-reactive protein - a promising biomarker of lupus nephritis","volume":"50","author":"Jakuszko","year":"2017","journal-title":"Clin Biochem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/ar1032","article-title":"Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus","volume":"6","author":"Sj\u00f6wall","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00655.x","article-title":"Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases","volume":"113","author":"Bell","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cca.2006.12.002","article-title":"Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins","volume":"378","author":"Sj\u00f6wall","year":"2007","journal-title":"Clin Chim Acta"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2002.0608","article-title":"Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren\u2019s syndrome, rheumatoid arthritis or inflammatory bowel disease","volume":"19","author":"Sj\u00f6wall","year":"2002","journal-title":"J Autoimmun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.021","article-title":"EULAR\/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia","volume":"84","author":"van Steenbergen","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"Pope","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108304","article-title":"Serum procalcitonin and C-reactive protein levels as diagnostic markers for distinguishing bacterial infections from lupus flares in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"101","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221106157","article-title":"The utility of erythrocyte sedimentation rate, C-reactive protein, and procalcitonin in detecting infections in patients with systemic lupus erythematosus: a systematic review","volume":"31","author":"Bruera","year":"2022","journal-title":"Lupus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1099800418803176","article-title":"Diet quality and high-sensitivity C-reactive protein in patients with systemic lupus erythematosus","volume":"21","author":"Pocovi-Gerardino","year":"2019","journal-title":"Biol Res Nurs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12916-024-03303-4","article-title":"Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials","volume":"22","author":"Zeng","year":"2024","journal-title":"BMC Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173820","article-title":"Usefulness of clinical and laboratory criteria for diagnosing autoimmune liver disease among patients with systemic lupus erythematosus: an observational study","volume":"10","author":"Heijke","year":"2021","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.24316","article-title":"C-reactive protein and systemic lupus erythematosus","volume":"59","author":"Gaitonde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ejcb.2011.09.008","article-title":"Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-\u03baB-dependent signaling","volume":"91","author":"Bode","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1425168","article-title":"C-reactive protein: structure, function, regulation, and role in clinical diseases","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245837","article-title":"The complex role of C-reactive protein in systemic lupus erythematosus","volume":"10","author":"Enocsson","year":"2021","journal-title":"J Clin Med"},{"key":"B32","article-title":"Serum C-reactive protein in primary Sjogren\u2019s syndrome","volume":"1","author":"Moutsopoulos","year":"1983","journal-title":"Clin Exp Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.08.004","article-title":"C-reactive protein: ligands, receptors and role in inflammation","volume":"117","author":"Mold","year":"2005","journal-title":"Clin Immunol"},{"key":"B34","article-title":"C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE","volume":"8","author":"Bravo","year":"1981","journal-title":"J Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/s101650200049","article-title":"Extremely high levels of C-reactive protein in patients with acute lupus serositis","volume":"12","author":"Ueki","year":"2002","journal-title":"Mod Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12890-022-01868-5","article-title":"Interstitial lung disease in primary Sjogren\u2019s syndrome","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S522156","article-title":"Time-dependent mortality predictors in primary Sjogren\u2019s syndrome: C-reactive protein for early risk and age for late outcomes","volume":"18","author":"Chen","year":"2025","journal-title":"J Inflammation Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12596","article-title":"Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.07.014","article-title":"Inflammation but not biliary obstruction is associated with carbohydrate antigen 19\u20139 levels in patients with primary sclerosing cholangitis","volume":"13","author":"Wannhoff","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset Still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.01.021","article-title":"EULAR\/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia","volume":"84","author":"van Steenbergen","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831536\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:55Z","timestamp":1778473435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831536\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1831536"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831536","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1831536"}}